A Phase 2, Open-Label Study of Rucaparib in Patients With Platinum-Sensitive, Relapsed, High-Grade Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (ARIEL2)
Status: Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 22 Oct 2019
Price : $35 *
At a glance
- Drugs Rucaparib (Primary)
- Indications Carcinoma; Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
- Focus Therapeutic Use
- Acronyms ARIEL2
- Sponsors Clovis Oncology
- 29 Sep 2019 According to a Clovis Oncology media release, data from this study were presented at the European Society for Medical Oncology (ESMO) Congress 2019.
- 29 Sep 2019 Results presented in a Clovis Oncology media release.
- 31 Jul 2019 Planned End Date changed from 1 Sep 2018 to 31 Oct 2021.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History